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Transforming growth factor 0 (TGF-0),' although first defined for its ability
to induce nonneoplastic cells to express a transformed phenotype, has now been
shown to exert multiple actions on both normalandtransformed cells (1) . Recent
studies have also defined a variety of immunoregulatory properties of TGF-0,
including inhibition ofTandB cell proliferation, IL-2-R induction, IL-1-induced
thymocyte proliferation, cytokine production, including IFN--y and TNF-a,
natural killer cell activity, andclass 11 antigen expression (2-6) . Themechanism(s)
through which TGF-0 exerts these immunoregulatory effects is at present not
known .
TNF-a (also referred to as cachectin) has also been shown to express multi-
functional immunomodulatory activities besides its direct cytotoxic/cytostatic
effects on transformed cells (7-10) . However, in contrast, to TGF-0, TNF-a
enhances IL-2-R expression, class II antigen expression, and IFN- ,y production
by activated lymphocytes (9, 10).
The contrasting immunoregulatory activities of these two proteins prompted
studies to further define their immunoregulatory activities in vitro . In this report,
we describe the dose-dependent inhibition ofCTL generation by TGF-0 and the
reversal of this inhibition by recombinant murine TNF-a (rMuTNF-a) . In
addition, we demonstrate that TNF-a is an important cytokine involved in CTL
development .
Materials and Methods
Animals .
￿
6-12-wk-old female BALB/c and C57BL/6 (B6) mice were obtained from
Charles River Breeding Laboratories (Wilmington, MA) .
Reagents .
￿
Porcine platelet-derived TGF-0 (R and D Systems, Minneapolis, MN) was
reconstituted in 4 mM HCl to 1 jug/ml and stored at 4°C. rMuTNF-a (sp act 7 X 107
U/mg), as determined by a standard cytotoxic bioassay using L-M cells, contained <0.025
pg of endotoxin per microgram protein by the limulus amoebocyte assay (11, 12) . The
specific activities of recombinant human TNF-a (rMuTNF-a) and -0 provided by Genen-
tech, Inc., as determined by the L-M bioassay were 5 X 107 and 2 X 10' U/mg protein,
respectively (13, 14) .
'Abbreviations used in this paper: CMEM, complete minimal essential medium; NRS, normal
rabbit serum ; TGF-0, transforming growth factor 0 .
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Mixed Lymphocyte Cultures (MLC).
￿
CTLs were generated in 5-d MLC by incubation in
24-well tissue culture plates (3524 ; Costar, Cambridge, MA) of 5 X 106 or 5 X 105 B6
responding spleen cells and 5 X 106 BALB/c stimulator spleen cells (irradiated 2,000 rad)
per well in 2 ml of complete minimal essential medium (CMEM) consisting of Eagle's
minimum essential medium supplemented with 0.1 mM nonessential amino acids, 2 mM
L-glutamine, penicillin (100 U/ml), and streptomycin (100 wg/ml) (Gibco, Grand Island,
NY) and 10% heat-inactivated FCS (Hyclone Laboratories, Inc ., Logan, UT) .
CTL Assay.
￿
After 5 d of culture, the cells were harvested, washed three times in
CMEM and tested for cytotoxic activity in a 4-h "Cr-release assay . P815 (DBA/2
mastocytoma, H-2d ; American Type Culture Collection, Rockville, MD) or LBRM-33-
1A5B (B10.BR lymphoma, H-2'; A . Zlotnik, DNAX Research Institute for Molecular and
Cellular Biology, Palo Alto, CA) were labeled with 150 jCi Na"Cr04 (5 MCi/ml ;
Amersham Corp., Arlington Heights, IL) for 45 min at 37°C, followed by three washes
in CMEM . 100 ,ul of target cells (105 cells/ml) and 100 u1 of effector cells at various
concentrations were added in triplicate in 96-well round-bottom microtiter plates (Costar) .
After 4 h of incubation at 37°C and 5% C02 in air, the supernatants were harvested
(Skatron, Rockville, MD) and their radioactivity was determined in an automatic gamma
counter (Micromedic Systems, Horsham, PA) . Percent specific cytotoxicity was calculated
as 100 X [cpm of test supernatants of effector cells and target cells incubated together
(experimental release)]- [cpm ofsupernatants oftarget cells incubated alone (spontaneous
release)]/{[cpm after lysis of target cells with 2% NP-40 (maximum release)] - [sponta-
neous release], . Results given are the mean of triplicate cultures ± SE . Spontaneous
release of target cells alone was <10% of maximum for all experiments.
Detection ofMuTNF-a in Supernatants oftheMLC .
￿
The quantity ofMuTNF-a produced
in the MLC was determined using the WEHI-164 clone 13, which is capable of detecting
levels as low as 7 X 10'U/ml (0.01 pg/ml) ofMuTNF-a per milliliter (15) . UsingWEHI-
164 clone 13 as indicator cells, the cytotoxicity induced by MuTNF-a was determined by
an MTT tetrazolium colorimetric assay as detailed previously (15) . The amount of
MuTNF-a in test supernatants was calculated on the basis of cytotoxicity obtained in the
presence of various dilutions of a rMuTNF-a standard . Data are expressed as units of
TNF-a per milliliter .
The specificity of this assay for MuTNF-a was demonstrated by inhibiting the cytolytic
activity of test supernatants with anti-rMuTNF-a antiserum produced in New Zealand
rabbits . This antiserum developed by methods similar to those described for production
of anti-rHuTNF-a antiserum (16), had a neutralization titer of ^-106 U/ml in the L-M
bioassay (12) . Normal rabbit serum(NRS) was obtained from control New Zealand rabbits .
Results
Inhibition ofCTL Generation by TGF-,B .
￿
Whenadded to MLC, TGF-,B inhibited
the generation of B6-anti-H-2'-specific CTL in a dose-dependent fashion (Table
1) . The inhibitory effects were most pronounced when TGF-# was added during
the first 24 h ofthe MLC (Fig . 1) . Less inhibition was observed when the addition
was delayed for 48 h, and only a minimal effect was seen if the delay was more
than 72 h . Similarly, at the doses tested TGF-# showed no inhibitory activity if
included directly in the CTL assay . These data indicate that TGF-# inhibits CTL
generation in a dose-dependent manner, and its mechanism of action appears to
involve early stages of the MLC .
Inhibition of TNF-a Production by TGF-,B duringMLC.
￿
Although a variety of
in vitro immunoregulatory activities have been ascribed to TNF-a, studies
examining the production ofTNF-a during an MLC and the effects of altering
endogenous TNF-a levels during CTL development have not been reported (8-
10) . Moreover, our previous studies have shown that TGF-# can inhibit TNF-a
production by murine macrophages (6) . Therefore, we considered it important.O
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* TGF-#wasadded at the start of culture.
$ P815 (H-2") target cells were used. Data are from one of three repre-
sentative experiments. Percent lysis against "Cr-labeled LBRM-33-
IA5B was <10% at 50 :1 E/T ratio .
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TABLE I
Effect of TGF-0 on In Vitro CTL Generation
FIGURE 2 .
￿
Inhibition of TNF-a production dur-
ing MLC by TGF-,6 . 300 ul were removed from
replicate MLC at the times indicated, and assayed
forTNF-a as described in Materials andMethods .
MLC contained no TGF-0 (0), 0.1 ng TGF-,B/ml
(0), or 1 .0 ng TGF-0/ml (0) . Thepresence of 10
,ug TGF-fl in the WEHI-164 MuTNF-a bioassay
did not affect the measurement of MuTNF-a ac-
tivity, while thepresence of anti-rMuTNF-a anti-
serumreduced the detection ofMuTNF-a to back-
ground levels . Standard errors for all determina-
tions were <10% . Results are presented as mean
of triplicate determinations of one of four repre-
sentative experiments . No significant amounts of
Culture Hours
￿
MuTNF-a were produced by cultures containing
B6 cells or irradiated BALB/c cells alone .
FIGURE 1 .
￿
Kinetics of TGF-0 inhibition ofCTLgener-
ation . 10 ng/ml TGF-# were added to MLC on days
shown. On day 5, this same concentration of TGF-,B was
added to theCTLassay . Data presented are the mean ±
SE of four independent experiments performed at an
E/T ratio of 25:1 . Similar results were obtained at all
E/T ratios tested (data not shown) .
to examine whether the inhibitory effects of TGF-0 on CTL development could
in part be due to the inhibition of TNF-a production . The concentration of
MuTNF-a was measured at various times during the first 48 h of MLC in the
absence or presence of 1 .0 or 0 .1 ng/ml TGF-f . The data (Fig . 2) indicate that
as early as 4 h after culture initiation, ^-7 X 10-s U/ml (0.1 pg/ml) of TNF-a
TGF-,B* Percent specific
51Cr release (± SE) at* E/T ratios of :
(ng/ml) 50 :1 25 :1 12.5 :1 6.25:1
None 89±2.0 89±4.0 86±0.4 75±1 .0
10 18±2.0 8±1.0 7±2.0 2±0.5
1.0 30±0.4 16±2.0 8±1 .0 3±1 .0
0.10 82±0.4 79±2.0 82±0.2 63±1 .0994
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TABLE II
Reversal of TGF-,B Inhibition ofCTL Generation by TNF-a
Treatment*
Control
10 ng/ml TGF-S
10 4 U/ml rMuTNF-a
10 ng/ml TGF-,B + rMuTNF-a at
10 5 U/ml
10 , U/ml
10 5 U/ml
10 2 U/ml
10' U/ml
* TGF-ft and/or rMuTNF-a were added to MLC on day 0 at concentrations indicated .
Data are from one of three representative experiments.
so
80
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0L_
rMuTNF-a (10U/ml)
Stimulator:Responder 0 .1 :1
Cell Ratio
0
12 .51 6 .25 :1 3 .13:1
Effector:Target Cell Ratio
FIGURE 3 .
￿
Effects of rMuTNF-a on CTL generation
during suboptimal culture conditions . MLC were estab-
lished at stimulator/responder ratios of 1 :1 (p) and0.1 :1
(p). 10 U/ml rMuTNF-a wasadded on day0 to MLC at
a 0.1 :1 ratio (®) and at a 1 :1 ratio (/) . Results are mean
± SE of triplicate determinations performed at an E/T
cell ratio of 12.5 :1 . Similar results were obtained at all
E/T cell ratios tested (data not shown).
1 .56 :1
Percent specific "Cr release (± SE) at
E/T ratios o£
FIGURE 4.
￿
Inhibition of CTL generation by
antibodies to rMuTNF-a . Rabbit serum poly-
clonal antibodies to rMuTNF-a was added at a
1 :100 final dilution on day 0 of MLC. MLC
contained : no antibodies (p); polyclonal anti-
bodies to rMuTNF-a (A) ; NRS(O) . Results are
mean ± SE of triplicate determinations . CTL
were washed three times in CMEM to prevent
carryover of antibodies to rMuTNF-a into the
"Cr assay .
25 :1 12.5 :1 6.25:1
83±5 .0 80±4.0 69±4.0
16±1 .0 12±3.0 7±2.0
83±2.0 85±4.0 78±1 .0
54±7 .0 35± 1 .0 21 ±0.6
62±3.0 48±1 .0 25±2.0
49±3.0 40±3.0 18±1 .0
28±1 .0 20±3.0 11±2.0
16±2.0 8±0.4 5±1 .0RANGES ET AL .
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can be detected and that TGF-0 suppresses the production ofTNF-a in a dose-
dependent manner .
To determine if the suppression of MuTNF-a production was critical to the
inhibitory activity of TGF-0 on CTL generation, exogenous rMuTNF-a was
added to MLC in the absence and presence of TGF-# (Table 11) . The addition
of 10 2 U/ml ofrMuTNF-a to TGF-0-suppressed MLC significantly restored the
CTL activity . These results are not due to any direct activity of rMuTNF-a on
the P815 target cells since the viability ofthese cellswas not affectedbyrMuTNF-
a doses as high as 105 U/ml. When rHuTNF-a was substituted for rMuTNF-a,
reversal of TGF-# suppression was detected only at concentrations of 105 U/ml
rHuTNF-a, and no activity was observed when rHuTNF-a was used at this same
concentration (data not shown) . These results may indicate a species preference
with regard to action of TNF-a in this context, as suggested in previous studies
(11) .
Enhancement ofCTL Development by rMuTNF-a .
￿
Under the optimal conditions
used in developing the CTLs, the addition ofrMuTNF-a at the doses tested had
only minimal enhancing activity . However, at a suboptimal responder/stimulator
ratio (0.1 :1), rMuTNF-a significantly enhanced both the proliferative response
(data not shown) and CTL generation to H-2d targets (Fig . 3) .
Inhibition ofCTL Generation by Antibodies to rMuTNF-a .
￿
As our earlier studies
demonstrated that rMuTNF-a can significantly enhance CTL development if
added to MLC established at suboptimal stimulator to responder ratios, we
considered it important to investigate whether antibodies to rMuTNF-a could
inhibit CTL generation . As shown in Fig. 4, the addition of rabbit polyclonal
antibodies to rMuTNF-a, but not addition ofNRS to MLCon day 0 significantly
inhibited CTL generation, further supporting our data of the critical role of
TNF-a during CTL development .
Discussion
We have investigated the effects ofTGF-0 and rMuTNF-a on CTL generation
and function . Our investigations have indicated that: (a) TGF-0 will inhibit, in a
dose-dependent manner, CTL generation, but only when TGF-0 is added in the
early stages of the MLC ; (b) TGF-,B does not inhibit the cytotoxic activity of
CTL ; (c) TNF-a production, which can be detected as early as 4 h after the
initiation of an MLC, is inhibited by TGF-# ; (d) addition ofrMuTNF-a to TGF-
,l-inhibited MLC significantly reverses the inhibitory activity of TGF-)3 ; and (e)
antibodies to rMuTNF-a significantly inhibit CTL development . These results
show that TGF-0 does not inhibit CTL generation by nonspecific cytostatic or
cytotoxic processes, since the addition ofTGF-,Q toMLC for the final 72 h does
not affect the CTL activity . Rather, TGF-0 appears to inhibit a differentiation
step in the early development of CTL . In addition, similar results have been
obtained with rHuTGF-(0 (the polypeptide sequence of mature human and
porcine TGF-,Q is identical) indicating that the effects observed with the natural
porcine preparation are mediated by TGF-0 alone, and not a contaminant (data
not shown) (17) .
Previous studies have indicated that CTL generation involves the production996
￿
IMMUNOMODULATION BY TRANSFORMING GROWTH FACTOR ,B
oftwo or more lymphokines, including IL-2 (18-21) . TGF-# has been shown to
affect T cell activation by downregulating IL-2-R . expression (2) and thereby
inhibiting T cell proliferation . Scheurich et al . (10) have reported that rHuTNF-
a can enhance the response to IL-2 by upregulating the expression of IL-2-R .
Our data indicate that TNF-a plays an important role in the generation of CTL,
and that TGF-,8 may inhibit the development of such cells, at least in part, by
inhibiting TNF-a production . Our data also demonstrate that, while the reversal
ofTGF-# suppression is significant, it is not complete, regardless of therMuTNF-
a dose used . 'This may point to multiple effects of TGF-,B on CTL generation,
only some of which are reversible by TNF-a, and which require the presence of
additional cytokines . In recent experiments, we have observed that IL-2, which
induces TNF-a production, can also reverseTGF-# inhibition ofCTL generation
(our unpublished observations) (22) . Thus, TGF-# may inhibit CTL generation
directly by downregulating IL-2-R expression, or indirectly by preventing up-
regulation of this receptor by blocking TNF-a production . Studies are now
under way to further investigate the role ofTNF-a in CTL generation, and the
suppression of that process by TGF-,B.
Summary
The immunoregulatory effects of transforming growth factor ,B (TGF-Q) and
recombinant murine tumor necrosis factor a (rMuTNF-a) on CTL generation
and activity were examined . The results demonstrate that TGF-,B, in a dose-
dependent manner, inhibited CTL generation but not CTL activity . The inhib-
itory effects were detected only when TGF-# was added within the first 48 h of
the MLC . Little activity was seen when it was added thereafter, including the
addition of TGF-# to the cytotoxicity assay . The production of TNF-a, which
occurs during early phases of the MLC and which is inhibited in the presence of
TGF-,B, appears to have an important regulatory role, as altering the levels of
TNF-a in an MLC can significantly influence CTL development . The inhibitory
effects of TGF-# on the MLC can be significantly reversed by the addition of
rMuTNF-a to the cultures . These results demonstrate that TGF-,B can inhibit
MLC and subsequent CTL generation at early stages of the reaction, and such
inhibition may involve the suppression ofTNF-a production .
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